Beyond Generics: How Zaynich™ is Positioning India as a Global Leader in Antibiotic Innovation
The global medical community has reached a dangerous crossroads: Antimicrobial Resistance (AMR). For decades, overuse and misuse of standard antibiotics have allowed bacteria to evolve into "superbugs" capable of resisting our most potent reserve drugs. As traditional pipelines dried up, clinicians faced a daunting question: What happens when the antibiotics run out? India has provided an answer. Developed by Mumbai-based pharmaceutical leader Wockhardt, Zaynich™ (a combination of cefepime and zidebactam) has secured regulatory approval from both India’s CDSCO and the US FDA. This milestone marks the first time a New Chemical Entity (NCE) discovered and developed entirely in India has earned US FDA approval, signaling a historic transition from manufacturing generic medicines to leading frontline global drug discovery. What is Zaynich™? Zaynich™ is an intravenous, novel combination antibiotic designed to combat highly resistant, hard-to-treat Gram-negative bacterial infecti...